somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
But being doomed seldom sounded so beautiful." AllMusic's Heather Phares viewed III as the duo's "most serious set of songs yet" and stated, "Artistic progress is as much about subtraction as it is about addition, and on III, Crystal Castles have made room to be sad, angry, pretty, and danceable at the same time." Pitchfork's Ian Cohen dubbed III "the duo's most focused record", adding, "While not as immediately striking as either Crystal Castles (I or II), the streamlined sound allows more maneuverability and subtle variety in the actual songwriting." Matt James of PopMatters wrote, "Perennial outsiders to the death, Crystal Castles' third act is inspiring, warped, feverishly uncomfortable, bold, bloody and brilliant." Dan Pfleegor of Consequence of Sound opined that "III is less playful than the duo's previous couple of offerings, but its thematic mood is much tighter and more fully realized." The Guardian's Tim Jonze noted that "witch house is an obvious influence [on the album], and you could question whether the former chip-tune terrorists are still as ahead of the curve as they once were. It hardly matters when they can come up with stuff like 'Child I Will Hurt You', a dream-state lullaby that is both beautiful and unbearably sorrowful." Simon Price of The Independent stated that the album "shudders and shimmers like some massive, monstrous machine.
Thiafentanil (A-3080, Thianil) is a highly potent opioid analgesic that is an analog of fentanyl, and was invented in 1986. Its analgesic potency is slightly less than that of carfentanil (itself approximately 10,000 times the potency of morphine, or 4,000 times that of heroin), though with a faster onset of effects, shorter duration of action and a slightly lesser tendency to produce respiratory depression. It is used in veterinary medicine to anesthetise animals such as impala, usually in combination with other anesthetics such as ketamine, xylazine or medetomidine to reduce the prevalence of side effects such as muscle rigidity.
=== Pulp stones === Pulp stones are calcified masses that occur in the pulp, either in the apical or coronal portions. They are classified according to their structure or location. According to their location, pulp stones can be classed either as free (completely surrounded by pulp), embedded (surrounded by dentine tissue) or adherent (attached to pulp wall continuous with dentine, but not fully enclosed). Depending on the structure, they are either true (dentine lined by odontoblasts), false (formed from degenerating cells that mineralise) or diffuse (more irregular in shape to false stones). The aetiology of pulp stones is little understood. It has been recorded that pulpal calcifications can occur due to:
==== Absorption ==== Pseudoephedrine is orally active and is readily absorbed from the gastrointestinal tract. Its oral bioavailability is approximately 100%. The drug reaches peak concentrations after 1 to 4 hours (mean 1.9 hours) in the case of the immediate-release formulation and after 2 to 6 hours in the case of the extended-release formulation. The onset of action of pseudoephedrine is 30 minutes.
==== 20th century ==== In response to concerns about the risks of occupational polonium exposure, quantities of 210Po were administered to five human volunteers at the University of Rochester from 1944 to 1947, in order to study its biological behaviour. These studies were funded by the Manhattan Project and the AEC. Four men and a woman participated, all suffering from terminal cancers, and ranged in age from their early thirties to early forties; all were chosen because experimenters wanted subjects who had not been exposed to polonium either through work or accident. 210Po was injected into four hospitalised patients, and orally given to a fifth. None of the administered doses (all ranging from 0.17 to 0.30 μCi kg−1) approached fatal quantities. The first documented death directly resulting from polonium poisoning occurred in the Soviet Union, on 10 July 1954. An unidentified 41-year-old man presented for medical treatment on 29 June, with severe vomiting and fever; the previous day, he had been working for five hours in an area in which, unknown to him, a capsule containing 210Po had depressurised and begun to disperse in aerosol form. Over this period, his total intake of airborne 210Po was estimated at 0.11 GBq (almost 25 times the estimated LD50 by inhalation of 4.5 MBq). Despite treatment, his condition continued to worsen and he died 13 days after the exposure event. From 1955 to 1957 the Windscale Piles had been releasing polonium-210.
Sources: en.wikipedia.org
== Function == Vitellogenin provides the major egg yolk protein that is a source of nutrients during early development of egg-laying (oviparous) vertebrates and invertebrates. Although vitellogenin also carries some lipid for deposition in the yolk, the primary mechanism for deposition of yolk lipid is instead via VLDLs, at least in birds and reptiles. Vitellogenin precursors are multi-domain apolipoproteins (proteins that bind to lipids to form lipoproteins), that are cleaved into distinct yolk proteins. Different vitellogenin proteins exist, which are composed of variable combinations of yolk protein components; however, the cleavage sites are conserved.
=== In print === Acererak is the final boss of the classic Dungeons and Dragons adventure module Tomb of Horrors; Acererak was also featured as the guardian of the Copper Key in the book Ready Player One by Ernest Cline. In the webcomic The Order of the Stick, the main villain Xykon is a lich. In the Harry Potter series, the main antagonist Voldemort commands armies of undead inferi and uses magical devices called horcruxes to store fragments of his soul in order to allow him to resurrect himself in the event that his body dies.
=== Stern === The Otto Stern model of the double layer is essentially a combination of Helmholtz and Gouy-Chapman theories. His theory states that ions do have finite size, so cannot approach the surface closer than a few nanometers. Through a distance known as the Stern Layer, ions can be adsorbed onto the surface up to a point referred to as the slipping plane, where the ions adsorbed meet the bulk liquid. At the slipping plane the potential Ψ has decreased to what is known as the zeta potential. Although zeta potential is an intermediate value, it is sometimes considered to be more significant than surface potential as far as electrostatic repulsion is concerned.
=== Class I === Class I fusion proteins resemble influenzavirus hemagglutinin in their structure. Post-fusion, the active site has a trimer of α-helical coiled-coils. The binding domain is rich in α-helices and hydrophobic fusion peptides located near the N-terminus (some examples show internal fusion peptides, however). Fusion conformation change can often be controlled by pH.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.